Advert - AstraZeneca – Case AUTH/3618/3/22

• Date posted
  16 June 2023
• Sanction
  Advertisement,
• Case number/s
  AUTH/3618/3/22 - Complainant v AstraZeneca

For misleading dosing claims on the Forxiga (dapagliflozin) promotional website, which had qualifying and important safety information for patients with severe hepatic impairment in a footnote that could have easily been missed by a health professional, AstraZeneca was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the
pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 6.2 - Providing misleading information which was not capable of
substantiation
Clause 11.2 - Promotion inconsistent with the summary of product characteristics
Clause 14.4 - Not encouraging the rational use of a medicine